Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (257)	1/5/1999 2:27:00 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3557

New angiogenic protein: Ang-3! TIE Ligand-3 or Angiopoetin-3, the new ligand homolog (agonist/antagonist) to TIE-2 receptor: United States Patent 5,851,797 Valenzuela , et al. December 22, 1998 Tie ligand-3, methods of making and uses thereof Abstract The present invention provides for an isolated nucleic acid molecule encoding TIE ligand-3. In addition, the invention provides for a receptorbody which specifically binds TIE ligand-3. The invention also provides an antibody which specifically binds TIE ligand-3. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human. Inventors: Valenzuela; David M. (Franklin Square, NY); Jones; Pamela F. (Fairfield, CT); Yancopoulos; George D. (Yorktown Heights, NY) Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Appl. No.: 665926 Filed: June 19, 1996 Claims 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding TIE ligand-3, wherein the nucleotide sequence is selected from the group consisting of: (a) the nucleotide sequence encoding TIE ligand-3 as set forth in FIGS. 21A and 21B (SEQ. ID NO.7); and (b) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) and encodes a ligand that binds TIE-2 receptor. ... ... The invention also provides for a TIE receptor antagonist as well as a method of inhibiting TIE ligand-3 biological activity in a mammal comprising administering to the mammal an effective amount of a TIE antagonist. According to the invention, the antagonist may be the TIE ligand-3 as described herein, an antibody or other molecule capable of specifically binding either TIE ligand-3 or TIE receptor, or ligandbody comprising the fibrinogen-like domain of TIE ligand-3. .... ... The TIE receptor/TIE ligand-3 interaction also provides a useful system for identifying small molecule agonists or antagonists of the TIE receptor. For example, fragments, mutants or derivatives of TIE ligand-3 may be identified that bind TIE receptor but do not induce any other biological activity. Alternatively, the characterization of TIE ligand-3 enables the determination of active portions of the molecule. Further, the identification of a ligand enables the determination of the X-ray crystal structure of the receptor/ligand complex, thus enabling identification of the binding site on the receptor. Knowledge of the binding site will provide useful insight into the rational design of novel agonists and antagonists. ...